Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System

This article was originally published in The Pink Sheet Daily

Executive Summary

The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.
Advertisement

Related Content

Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate
Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny
FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Topics

Advertisement
UsernamePublicRestriction

Register

PS072446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel